Veracyte (VCYT) Capital Expenditures (2012 - 2026)

Veracyte has disclosed Capital Expenditures across 15 years of filings, most recently posting $2.9 million for Q2 2026.

• In Q2 2026, Capital Expenditures rose 122.32% year-over-year to $2.9 million; the TTM figure through Jun 2026 stood at $12.4 million (up 30.62% YoY), while the FY2025 annual figure was $9.7 million, down 14.26% from the prior year.
• Capital Expenditures came in at $2.9 million for Q2 2026 at Veracyte, down from $3.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $4.1 million in Q4 2024 to a low of $1.3 million in Q2 2025.
• Average Capital Expenditures over 5 years is $2.5 million, with a median of $2.5 million recorded in 2022.
• Year-over-year, Capital Expenditures soared 122.59% in 2022 and slumped 53.57% in 2025.
• Over 5 years, Capital Expenditures stood at $1.9 million in 2022, then soared by 33.39% to $2.5 million in 2023, then soared by 65.84% to $4.1 million in 2024, then slipped by 8.72% to $3.8 million in 2025, then fell by 24.37% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $2.9 million in Q2 2026, $3.0 million in Q1 2026, and $3.8 million in Q4 2025.